Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk

被引：0

作者：

Inzucchi, Silvio E. ^{[1
]}

Wanner, Christoph ^{[2
]}

Lachin, John M. ^{[3
]}

Fitchett, David ^{[4
]}

Bluhmki, Erich ^{[5
]}

Hantel, Stefan ^{[5
]}

Mattheus, Michaela ^{[6
]}

Devins, Theresa ^{[7
]}

Johansen, Odd Erik ^{[8
]}

Woerle, Hans Juergen ^{[8
]}

Broedl, Uli C. ^{[9
]}

Zinman, Bernard ^{[10
,11
,12
]}

机构：

[1] Yale Univ, Sch Med, Endocrinol Sect, New Haven, CT USA

[2] Wurzburg Univ Clin, Div Nephrol, Dept Med, Wurzburg, Germany

[3] George Washington Univ, Biostat Unit, Rockville, MD USA

[4] St Michaels Hosp, Div Cardiol, Toronto, ON M5B 1W8, Canada

[5] Boehringer Ingelheim Pharma GmbH & Co KG, Global Biometr & Datamanagement, Biberach, Germany

[6] Boehringer Ingelheim Pharma GmbH & Co KG, Global Biometr & Datamanagement, Ingelheim, Germany

[7] Boehringer Ingelheim Pharmaceut Inc, Clin Operat, Ridgefield, CT USA

[8] Boehringer Ingelheim Norway KS, Therapeut Area Metab, Asker, Norway

[9] Boehringer Ingelheim Pharma GmbH & Co KG, Therapeut Area Metab, Ingelheim, Germany

[10] Mt Sinai Hosp, Lunenfeld Tanenbaum Rsch Inst, Toronto, ON M5G 1X5, Canada

[11] Mt Sinai Hosp, Div Endocrinol, Toronto, ON M5G 1X5, Canada

[12] Univ Toronto, Toronto, ON, Canada

来源：

CIRCULATION | 2015年 / 132卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

20238

引用

页码：2271 / 2271

页数：1

共 50 条

[1] Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
Zinman, Bernard
Inzucchi, Silvio E.
Lachin, John M.
Wanner, Christoph
Fitchett, David
Kohler, Sven
Mattheus, Michaela
Biomath, Dipl
Woerle, Hans J.
Broedl, Uli C.
Johansen, Odd Erik
Albers, Gregory W.
Diener, Hans Christoph
STROKE, 2017, 48 (05) : 1218 - +
[2] Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus
Jaeschke, Roman
Gerstein, Hertzel
POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (10): : 803 - 805
[3] Cost-utility of empagliflozin in patients with type 2 diabetes mellitus at high cardiovascular risk
Weeda, Erin
Nguyen, Elaine
Coleman, Craig
Nair, Suresh
PHARMACOTHERAPY, 2017, 37 (12): : E168 - E168
[4] Empagliflozin and cardiovascular endpoints in patients with type 2 diabetes mellitus
Guthoff M.
Der Nephrologe, 2016, 11 (3): : 217 - 218
[5] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND
Pawlik, D.
Wojcik, R.
Zawodnik, A.
Kaczor, M. P.
VALUE IN HEALTH, 2017, 20 (09) : A478 - A478
[6] Empagliflozin and cardiovascular outcomes in type 2 diabetes
Gregory B. Lim
Nature Reviews Cardiology, 2016, 13 (1) : 3 - 3
[7] Risk Factors and cardiovascular Outcomes in Patients with type 2 Diabetes Mellitus
Pavlicek, Vojtech
DIABETOLOGE, 2018, 14 (07): : 499 - 500
[8] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Leitner, H.
AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2016, 9 (01): : 22 - 22
[9] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Leitner, H.
JOURNAL FUR KARDIOLOGIE, 2016, 23 (1-2): : 54 - 54
[10] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Rosenstein, Robert
Hough, Augustus
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (11): : 1093 - 1094

← 1 2 3 4 5 →